Drugs / Q-1802
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04856150 | May 2021 → Apr 2024 | cancer | QureBio Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05964543 | Jun 2023 → Aug 2024 | gastroesophageal junction adenocarcinoma | QureBio Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q-1802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04856150 ↗ |
| Route | Intravenous | “Q-1802 will be administered intravenously.” NCT04856150 ↗ |